Cost-Consequence Analysis of Three Different Diagnostic Strategies in the First- and Second-Line Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
DOI:
https://doi.org/10.7175/fe.v19i1.1354Keywords:
Liquid biopsy, Tissue biopsy, Cost-consequence analysis, NSCLC, Italian NHSAbstract
BACKGROUND: Unlike the tissue one, liquid biopsy is a less invasive diagnostic method for the assessment of possible mutations of the tumor, based on the analysis of circulating free DNA (cfDNA) present in the plasma component of the blood. Because blood samples are easily obtainable, plasma biopsy is a non-invasive method, supplementing the more traditional biopsy techniques.AIM: A cost-consequence analysis was conducted to compare the adoption of three different diagnostic strategies in the first- and second-line treatment of locally advanced or metastatic NSCLC: i) tissue strategy (only tissue biopsy for first and second line), ii) combined strategy (first line: tissue biopsy. If unknown, liquid biopsy; second line: liquid biopsy. If negative, tissue biopsy) and iii) potential strategy (first line: tissue biopsy. If unknown or tissue ineligible, liquid biopsy; second
line: liquid biopsy. If negative, tissue biopsy).
METHODS: A decision-analytic model was developed considering the Italian NHS’s perspective. We only evaluated direct medical costs (tissue biopsy, management of complications associated with tissue and liquid biopsies) borne by the NHS. The CCA was conducted over a time horizon of 1 year, assuming that for each patient with mNSCLC the diagnostic
pathway (first- and second-line treatment) ended within such period. Key variables were tested in the sensitivity analysis.
RESULTS: Considering both the first and the second line of treatment, the potential strategy constitutes the cost-effective alternative, characterized by an average cost per correctly identified case (€ 685) lower than that estimated for the combined strategy (€ 732) or for the tissue strategy (€ 1,004). The potential strategy remains cost-effective, also considering the results referred to the first- or second-line treatment only.
CONCLUSION: The choice of a correct diagnostic strategy is crucial in order to optimize cancer therapies in the first- and second-line treatment of locally advanced or metastasized NSCLC. The addition to the diagnostic pathway of the liquid biopsy would correctly identify a greater number of cases, supporting the prescription of the best oncological therapy.
References
AIOM, AIRTUM e Fondazione AIOM. I numeri del cancro in Italia 2017. Available at http://www.aiom.it/fondazione-aiom/+aiom-airtum-numeri-cancro-2017/1,3021,0 (last accessed January 2018)
Lim C, Sung M, Shepherd FA, et al. Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? J Thorac Oncol 2016; 11: 79-84; https://doi.org/10.1016/j.jtho.2015.09.006
Gobbini E, Galetta D, Tiseo M, et al. Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. Lung Cancer 2017; 111: 30-7; https://doi.org/10.1016/j.lungcan.2017.06.009
Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013; 8: 992-1001; https://doi.org/10.1200/JCO.2012.46.9270
Chouaid C, Dujon C, Do P, et al. Feasibility and clinical impact of re-biopsy in advanced non-small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer 2014; 86: 170-3; https://doi.org/10.1016/j.lungcan.2014.08.016
Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011; 6: 1379-91; https://doi.org/10.1097/JTO.0b013e318220cb8e
Peters S, Adjei AA, Gridelli C, et al. ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: 7:vii56-64; https://doi.org/10.1093/annonc/mds226
Fondazione AIOM. La biopsia liquida Informazioni per i pazienti (a cura di Alessandro Inno e Giulio Metro). Available at http://www.aiom.it/biopsia-liquida/fondazione-aiom/opuscoli-informativi-pazienti/biopsia-liquida/1,3902,1 (last accessed January 2018)
Jamal-Hanjani M, Quezada SA, Larkin J, et al. Translational implications of tumor heterogeneity. Clin Cancer Res 2015; 21: 1258-66; https://doi.org/10.1158/1078-0432.CCR-14-1429
Sun JF, Ahn MJ, Choi YL, et al. Clinical implications of T790M mutation inpatients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 2013; 82: 294-8; https://doi.org/10.1016/j.lungcan.2013.08.023
Diaz LA, Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014; 32: 579-86; https://doi.org/10.1200/JCO.2012.45.2011
Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. JAMA 1996; 276: 1172-7; https://doi.org/10.1001/jama.1996.03540140060028
Mauskopf JA, Paul JE, Grant DM. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics 1998; 13: 277-88; https://doi.org/10.2165/00019053-199813030-00002
AIOM, AIRTUM e Fondazione AIOM. I numeri del cancro in Italia 2016. Available at http://www.registri-tumori.it/PDF/AIOM2016/I_numeri_del_cancro_2016.pdf (last accessed January 2018)
Draheim S, Eisinger B, Förster S, et al. Krebsinzidenz und Krebsmortalität 2009-2012. Available at https://www.berlin.de/gkr/_assets/jahresbericht-2009-2012.pdf (last accessed January 2018)
Malapelle U, Sirera R, Jantus-Lewintre E, et al. (2017) Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn 2017; 17: 209-15; https://doi.org/10.1080/14737159.2017.1288568
Jenkins S, Yang JC, Ramalingam SS, et al. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer. J Thorac Oncol 2017; 12: 1061-70; https://doi.org/10.1016/j.jtho.2017.04.003
Cheng MM, Palma JF, Scudder S, et al. The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer. J Pers Med J 2017; 7; https://doi.org/10.3390/jpm7030005
Yoon HJ, Lee HY, Lee KS, et al. Repeat Biopsy for Mutational Analysis of Non–Small Cell Lung Cancers Resistant to Previous Chemotherapy: Adequacy and Complications. Radiology 2012; 265: 939-48; https://doi.org/10.1148/radiol.12112613
Tariffe delle prestazioni di assistenza ospedaliera per acuti (sistema DRG). Supplemento ordinario n. 8 alla Gazzetta Ufficiale Serie generale - n. 23 del 28-1-2013
Accordo interregionale per la compensazione della mobilità sanitaria. Conferenza delle regioni e delle province autonome. Versione in vigore per le attività dell’anno 2012. Roma 16 maggio 2013
AIES, Associazione Italiana di Economia Sanitaria. Proposte di linee guida per la valutazione economica degli interventi sanitari. Pharmacoeconomics Italian Research Articles 2009; 11: 89-93
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
